Verici Dx plc (VRCI) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to the Verici DX PLC Business Update. Throughout the recorded update, investors will be in listen-only mode. Questions are encouraged and can be submitted at any time by the Q&A tab situated in the right-hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all the questions submitted today and publish responses where it is appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to CEO, Sarah. Welcome everybody. Thanks for attending. This is the half year results and business update. Obviously there is our disclosure slide. I'd like to kick off by presenting the slide that I have presented before and then showing how we are translating this into our current view of the business. This has been our vision slide for how we operate with the company. You can see the kidney transplant testing, the suite of products being pre-transplant for Arthur, early stage damage, post-transplant to tibia, late stage Protega. Collectively, those three tests have covered the end-to-end spectrum of testing in kidney transplants. And we have always maintained that there will be a movement from individual tests to more solutions based offering as we look at the integration of those three tests. Collectively and with other programs, we have called this the clinicians platform and indicated that each area of those tests are and will be developed as applicable to other organs outside of kidney, the usual transplant organs of heart, liver and lung, and can be applied and extended into adjacent diseases such as autoimmune diseases. Behind that, we've talked about a re...